A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19–Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: COVID-19 | ARDS | COVID19 | COVID | ventilation
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Eligibility Criteria:

•    Participant or health proxy must provide informed consent before any study assessment is performed.
•    Male or female participants aged ≥ 18 years.
•    Participants with coronavirus (SARS-CoV-2) infection confirmed ≤ 2 weeks prior to randomization by any test with local regulatory approval.
•    Participants who are intubated and receiving mechanical ventilation due to COVID-19–associated ARDS and have a PaO2/FiO2 of
≤ 300 mmHg within 6 hours of randomization.
•    Participants with lung imaging showing bilateral or diffuse pulmonary infiltrates on chest x-ray or CT scan.

Recruitment Status

Enrolling By Invitation

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.